Why Nobody Has P450scc (20,22 Desmoslase) Deficiencyg

Walter L. Miller

University of California, San Francisco San Francisco, California 94143-0978

Okuyama et al. (1) recently reported a case of congenital lipoid adrenal hyperplasia (lipoid CAH) caused by a splicing mutation in the gene for the steroidogenic acute regulatory protein (StAR). In citing the relevant literature, they pointed out that nearly all patients with the lipoid CAH phenotype have been found to have StAR mutations. In two large series, Bose et al. (2) and Nakae et al. (3) found StAR mutations in 39 of 40 patients. Lipoid CAH was formerly misnamed 20,22 desmolase deficiency and was thought to be caused by mutations in P450scc (4, 5, 6), the cholesterol-side chain cleavage enzyme that converts cholesterol to pregnenolone, but these patients were recently shown to lack P450scc mutations (7) and have StAR mutations (8). Nevertheless, three factors have contributed to the persistence of the notion that some of these patients may harbor P450scc mutations: first, the weight of history and the lingering misnomer of 20,22 desmolase deficiency; second, the failure to find a StAR mutation in Bose’s patient #14 (2); third and most important, the description by Yang et al. that rabbits that are homozygous for P450scc gene deletions have a phenotype that very closely corresponds with lipoid CAH (9). While we cannot be certain that all patients with lipoid CAH will have StAR mutations (especially in view of Bose’s patient #14), we can be quite confidant that P450scc mutations will never be found in a liveborn human being. The reasons for this were outlined recently (10) but are presented in more detail below.

As shown by numerous biochemical experiments (for review see 11) and proven by the P450scc deficient rabbit of Yang et al. (9), P450scc is the only enzyme that can convert cholesterol to pregnenolone, which is the needed precursor for the production of progesterone. Progesterone is required for the maintenance of mammalian pregnancy (for review see 12); without progesterone, uterine contractions and spontaneous abortion occur. During pregnancy, there are two potential sources of progesterone—the corpus luteum of the mother’s ovary and the placenta. These are fundamentally different: the corpus luteum is maternal tissue, but the steroidogenic syncytiotrophoblasts of the placenta are fetal tissue. In rabbits (and goats), the corpus luteum secretes progesterone throughout pregnancy (13), so that a disorder in placental progesterone secretion will not adversely affect the pregnancy. In these animals, placental choriogonadotropin is needed to maintain the maternal corpus luteum, but the placenta is not needed to produce progesterone (14). By contrast in human beings, the corpus luteum secretes progesterone only during the first trimester; placental progesterone becomes sufficient to maintain pregnancy only after about 6 weeks gestation; the so-called "luteoplacental shift" (13, 15). Consequently human maternal ovariectomy in the first 6 weeks will cause spontaneous abortion, but maternal ovariectomy thereafter will not (13, 15).

Thus in the rabbit, a homozygous P450scc mutation in the fetus will not disrupt progesterone production by the heterozygous mother, and the pregnancy will be carried to term. By contrast a human fetus homozygous for a P450scc mutation will spontaneously abort at about 6–7 weeks, when production of progesterone from the maternal corpus luteum wanes, and the mutant placental system is unable to take over. This same physiology explains why mutations have never been found in the human genes for the proteins that transfer electrons to P450scc, ferredoxin reductase and ferredoxin. Similarly, placental production of progesterone requires 3ß-hydroxysteroid dehydrogenase (3ßHSD). The placental form of this enzyme (3ßHSD-I) is encoded by a different gene that the 3ßHSD-II gene expressed in the adrenals and gonads. Thus all patients with 3ßHSD deficiency have mutations in the adrenal/gonadal 3ßHSD-II but never in 3ßHSD-I (16), as 3ßHSD-I is required for placental production of progesterone.

Fetuses with StAR mutations causing lipoid CAH reach term because their placentas continue to produce progesterone (17). The placenta does not express StAR (18) and produces progesterone through a poorly-characterized process called StAR-independent steroidogenesis (2), which may involve the StAR-like protein MLN-64 (19). However, consideration of the genetics of progesterone production by the maternal-fetal-placental unit tells us that human fetuses with homozygous mutations for any of the genes required for placental production of progesterone will not survive to the time of delivery.

Footnotes

Address correspondence to: Walter L. Miller, M.D., Professor, Department of Pediatrics, University of California, San Francisco, Bldg. MR-4, Room 209, San Francisco, California 94143-0978.

Received November 24, 1997.

References

  1. Okuyama E, Nishi N, Onishi S, et al. 1997 A novel splicing junction mutation in the gene for the steroidogenic acute regulatory protein causes congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab. 82:2337–2342.[Abstract/Free Full Text]
  2. Bose HS, Sugawara T, Strauss III JF, Miller WL. 1996 The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. New Engl J Med. 335:1870–1878.[Abstract/Free Full Text]
  3. Nakae J, Tajima T, Sugawara T, et al. 1997 Analysis of the steroidogenic acute regulatory protein (StAR) gene in Japanese patients with congenital lipoid adrenal hyperplasia. Hum Mol Genet. 6:571–576.[Abstract/Free Full Text]
  4. Degenhart HJ, Visser KHA, Boon H, O’Doherty NJD. 1972 Evidence for deficiency of 20{alpha} cholesterol hydroxylase activity in adrenal tissue of a patient with lipoid adrenal hyperplasia. Acta Endocrinol (Copenh) 71:512–518.
  5. Koizumi S, Kyoya S, Miyawaki T, et al. 1977 Cholesterol side-chain cleavage enzyme activity and cytochrome P450 content in adrenal mitochondria of a patient with congenital lipoid adrenal hyperplasia (Prader disease). Clin Chim Acta. 77:301–306.[CrossRef][Medline]
  6. Hauffa BP, Miller WL, Grumbach MM, Conte FA, Kaplan SL. 1985 Congenital adrenal hyperplasia due to deficient cholesterol side-chain cleavage activity (20,22 desmolase) in a patient treated for 18 years. Clin Endocrinol (Oxf). 23:481–493.[Medline]
  7. Lin D, Gitelman SE, Saenger P, Miller WL. 1991 Normal genes for the cholesterol side chain cleavage enzyme, P450scc, in congenital lipoid adrenal hyperplasia. J Clin Invest. 88:1955–1962.[Medline]
  8. Lin D, Sugawara T, Strauss III JF, et al. 1995 Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science. 267:1828–1831.[Medline]
  9. Yang X, Iwamoto K, Wang M, Artwohl J, Mason JI, Pang S. 1993 Inherited congenital adrenal hyperplasia in the rabbit is caused by a deletion in the gene encoding cytochrome P450 cholesterol side-chain cleavage enzyme. Endocrinology. 132:1977–1982.[Abstract]
  10. Bose HS, Pescovitz OH, Miller WL. 1997 Spontaneous feminization in a 46,XX female patient with congenital lipoid adrenal hyperplasia caused by a homozygous frame-shift mutation in the steroidogenic acute regulatory protein. J Clin Endocrinol Metab. 82:1511–1515.[Abstract/Free Full Text]
  11. Miller WL. 1988 Molecular biology of steroid hormone synthesis. Endocr Rev. 9:295–318.[Medline]
  12. Strauss JF, III, Gåafvels ME, King BF. 1995 Placental hormones. In: L.J. DeGroot, ed. Endocrinology. Philadelphia: Saunders; pp 2171–2206.
  13. Csapo AI, Pulkkinen MO. 1978 Indispensibility of the human corpus luteum in the maintenance of early pregnancy: Luteectomy evidence. Obstet Gynecol Surv. 83:69–81.
  14. Porter DG, Becker R, Csapo A. 1968 On the mechanism of action of intraamniotic hypertonic saline treatment in rabbits. J Reprod Fertil. 17:433–442.[CrossRef][Medline]
  15. Csapo AI, Pulkkinen MO, Wiest WB. 1973 Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol. 115:759–765.[Medline]
  16. Simard J, Rhéaume E, Sanchez R, et al. 1993 Molecular basis of congenital adrenal hyperplasia due to 3ß- hydroxysteroid dehydrogenase deficiency. Mol Endocrinol. 7:716–728.[Abstract]
  17. Saenger P, Klonari Z, Black SM, et al. 1995 Prenatal diagnosis of congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab. 80:200–205.[Abstract]
  18. Sugawara T, Holt JA, Driscoll D, et al. 1995 Human steroidogenic acute regulatory protein (StAR): Functional activity in COS-1 cells, tissue-specific expression, and mapping of the structural gene to 8p11.2 and an expressed pseudogene to chromosome 13. Proc Natl Acad Sci USA. 92:4778–4782.[Abstract]
  19. Watari H, Arakane F, Moog-Lutz C, et al. 1997 MLN64 contains a domain with homology to the steroidogenic acute regulatory protein (StAR) that stimulates steroidogenesis. Proc Natl Acad Sci USA. 94:8462–8467.[Abstract/Free Full Text]